pyridoxine + amino acids

pyridoxine + amino acids is an investigational combination therapy developed by Changzhou Wujin People's Hospital for the treatment of amyotrophic lateral sclerosis (ALS). This therapeutic approach combines pyridoxine (Vitamin B6), a vital coenzyme in amino acid metabolism and neurotransmitter synthesis, with a mixture of essential and non-essential amino acids. The rationale for this combination in ALS is to provide metabolic support to stressed motor neurons, potentially reducing glutamate-mediated excitotoxicity by facilitating the conversion of glutamate to GABA via pyridoxal phosphate-dependent glutamate decarboxylase. Additionally, the amino acid component aims to address the hypermetabolic state and muscle wasting characteristic of ALS. A Phase 2 clinical trial (NCT02442687) was initiated to evaluate the efficacy of this combination in slowing disease progression and improving the quality of life for ALS patients.

Other names

Vitamin B6 and amino acidspyridoxine and amino acids